<DOC>
	<DOCNO>NCT01346293</DOCNO>
	<brief_summary>The study design compare safety immunogenicity DTap-IPV DAPTACEL® + IPOL® 5th dose booster child ≥ 4 &lt; 7 year age US Puerto Rico previously vaccinate DAPTACEL® and/or Pentacel® vaccine . Primary Objectives : - To compare pertussis [ Pertussis Toxoid ( PT ) , Filamentous Haemagglutinin ( FHA ) , Pertactin ( PRN ) , Fimbriae Types 2 3 ( FIM ) ] booster response geometric mean concentration ( GMCs ) ( measure enzyme-linked immunosorbent assay [ ELISA ] ) follow DTap-IPV vaccination elicit follow DAPTACEL® + IPOL® vaccination administer 5th dose . - To compare diphtheria tetanus booster response GMCs ( measure ELISA ) follow DTap-IPV vaccination elicit follow DAPTACEL® + IPOL® vaccination administer 5th dose . - To compare Inactivated Poliovirus Vaccine booster response ( measure neutralize assay ) follow DTap-IPV vaccination elicit follow DAPTACEL® + IPOL® vaccination . Observational Objectives : - To compare polio ( type 1 , 2 , 3 ) geometric mean titer ( GMTs ) follow DTap-IPV vaccination elicit follow DAPTACEL® + IPOL® vaccination . - To assess safety DTap-IPV vaccine DAPTACEL® + IPOL® vaccine administer fifth dose booster vaccine participant previously vaccinate DAPTACEL and/or Pentacel vaccine .</brief_summary>
	<brief_title>Study DTap-IPV Compared DAPTACEL® IPOL® 5th Dose Children 4 6 Years Age</brief_title>
	<detailed_description>All participant randomize receive either one dose DTap-IPV + Measles , Mumps , Rubella Virus Vaccine Live ( M-M-R®II ) + VARIVAX® one dose DAPTACEL® + IPOL® + M-M-R®II + VARIVAX® Day 0 .</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Tetany</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged ≥ 4 &lt; 7 year day inclusion Informed consent form sign dated parent/guardian first studyrelated procedure Subject parent/guardian able attend schedule visit comply trial procedure Subject document completion primary infant series booster DAPTACEL® and/or Pentacel® vaccine ( ) . Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede trial vaccination Planned participation another clinical trial present trial period Receipt vaccine 4 week precede trial vaccination , except influenza vaccine , may receive least 2 week study vaccine Planned receipt vaccine 4 week follow trial vaccination except influenza vaccine , may receive least 2 week study vaccine Receipt blood bloodderived product past 3 month Known suspected congenital acquire immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) History human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C History diphtheria , tetanus , pertussis infection , confirm either clinically , serologically , microbiologically Known systemic hypersensitivity vaccine ' component , history lifethreatening reaction vaccine use trial vaccine contain substance Laboratoryconfirmed thrombocytopenia , contraindicate intramuscular vaccination Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular vaccination Chronic illness , opinion Investigator , stage might interfere trial conduct completion Identified employee Investigator study center , direct involvement propose study study direction Investigator study center , well family member ( i.e. , immediate , husband , wife child , adopt natural ) employee investigator .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Tetanus</keyword>
	<keyword>Diphtheria</keyword>
	<keyword>Pertussis</keyword>
	<keyword>DTap-IPV</keyword>
	<keyword>DAPTACEL®</keyword>
	<keyword>VARIVAX®</keyword>
</DOC>